Market news

Kimberly-Clark has raised its dividend through every recession of the past two decades, but a $48.7 billion acquisition and free cash flow that already fell short of last year's dividend payment put that streak in genuine jeopardy.

This article first appeared on GuruFocus. Kenvue Inc (NYSE:KVUE) recently announced a total dividend of $0.21 per share, with the ex-dividend date set for 2026-09-21. For income-focused investors, the ex-dividend date is a critical marker: shareholders must own the stock before this date to qualify for the payment.

One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.

Kenvue Inc. previously announced that its Board of Directors declared a quarterly dividend of US$0.21 per share, payable on October 2, 2026, to shareholders of record as of September 21, 2026, while also securing FDA approval for TYLENOL with Naproxen, a first-of-its-kind non-opioid OTC pain reliever backed by multiple clinical studies. By pairing a new, clinically supported TYLENOL with Naproxen launch with ongoing cash returns via dividends, Kenvue is highlighting both product innovation...

Kimberly-Clark rated Hold: The Kenvue deal adds EPS/FCF uncertainty, share dilution, and new debt. Click for more on KMB stock.

Kenvue (KVUE) is on investors’ radar after launching TYLENOL with Naproxen, an FDA-approved, opioid-free over the counter pain reliever that combines acetaminophen and naproxen sodium, backed by extensive clinical research. That launch comes as Kenvue’s share price has softened in the short term, with a 7 day share price return of down 4.43% and a 30 day share price return of down 6.72%. Even though the year to date share price return is 3.41% and the 1 year total shareholder return is 2.85%,...

Kimberly-Clark Corporation (NASDAQ:KMB) is preparing asset sales to address EU antitrust concerns surrounding its planned $40 billion acquisition of Kenvue, according to Reuters. The company is reportedly seeking to offer remedies that could secure European Commission approval by the September 29 deadline, avoiding a more extensive four-month investigation. Similar regulatory concerns have already emerged in […]

Motley Fool Press Release.

Kimberly-Clark may offer concessions to ease EU antitrust scrutiny of its $40B Kenvue deal as regulators weigh a deeper probe.

Kimberly-Clark weighs asset sales to address EU antitrust concerns over its $40B Kenvue deal.

Sorbent Paper Company Pty Ltd ("Sorbent") has signed an agreement with Kenvue's Singaporean subsidiary to acquire its Stayfree and Carefree feminine care business in Australia and New Zealand. Following completion of the transaction, the business in New Zealand will be managed by Sorbent's affiliate, Cottonsoft.

Kimberly-Clark just raised its dividend for the 54th straight year while simultaneously chasing a nearly $50 billion acquisition, and income investors are now weighing whether a deal of that size can coexist with a payout that costs over $1.6 billion annually.

SUMMIT, N.J., September 10, 2026--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock. The quarterly dividend is payable on October 2, 2026, to shareholders of record as of the close of business on September 21, 2026.

Kimberly-Clark Corporation’s (NASDAQ:KMB) proposed $40 billion takeover of Kenvue has entered another stage of regulatory review. Documents on the European Commission’s website show that Kimberly-Clark has requested EU permission to complete the transaction, which was first announced in November 2025. The deal would combine Kimberly-Clark (NASDAQ:KMB) with a large portfolio of consumer-health brands, including Tylenol, […]

KVUE nears its planned combination after shareholder and U.S. antitrust clearances, while margin, debt and legal risks temper the Q4 2026 outlook.

Kimberly-Clark's (KMB) proposal to acquire Kenvue (KVUE) received approval from Australia's competit

Deal skepticism and litigation fears still weigh on this consumer staples stalwart.

Kimberly-Clark (KMB) stock is in focus after the company named Suzana Blades as Senior Vice President and General Counsel, with a future role tied to its pending acquisition of Kenvue Inc. Kimberly-Clark shares trade at US$110.34, with the stock up 10.2% over the past 90 days and 8.8% year to date on a share price basis, even though the 1 year total shareholder return has declined 11.1%. This points to improving short term momentum alongside a weaker longer term experience for...

Kenvue stock has delivered a 9.3% gain year to date. Its current share price of US$18.93 still sits well below an intrinsic value estimate from a Discounted Cash Flow (DCF) model, which points to a 36.4% discount. At the same time, traditional earnings multiples suggest the shares look about fairly priced, leaving investors weighing a clear DCF upside signal against more neutral market ratios. Year to date, Kenvue is up 9.3%, indicating the market has already repriced the stock higher even...

Zyrtec Allergen Shield Spray, a new drug free nasal mist from Kenvue (KVUE), has given investors fresh product news to weigh. The launch highlights activity in the company’s Self Care allergy portfolio. See our latest analysis for Kenvue. The recent Zyrtec Allergen Shield Spray launch comes after Kenvue reported second quarter 2026 sales of US$3,955 million and net income of US$456 million on August 6, while also completing a US$439.14 million share repurchase program that covered 20,387,000...